Capricor Therapeutics, Inc. Forecast, price target & analysts
Capricor Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Capricor Therapeutics, Inc. Classifications & Recommendation:
Capricor Therapeutics, Inc. Price Target
| Target Price | $44.88 |
| Price | $29.68 |
| Potential |
51.21%
register free of charge
|
| Number of Estimates | 12 |
|
12 Analysts have issued a price target Capricor Therapeutics, Inc. 2026 .
The average Capricor Therapeutics, Inc. target price is $44.88.
This is
51.21%
register free of charge
$63.00
112.26%
register free of charge
$20.20
31.94%
register free of charge
|
|
| A rating was issued by 16 analysts: 15 Analysts recommend Capricor Therapeutics, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Capricor Therapeutics, Inc. stock has an average upside potential 2026 of
51.21%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 22.27 | 0.61 |
| 11.56% | 97.25% | |
| EBITDA Margin | -81.23% | -17,266.67% |
| 327.90% | 21,156.43% | |
| Net Margin | -181.72% | -16,442.28% |
| 105.29% | 8,947.93% |
12 Analysts have issued a sales forecast Capricor Therapeutics, Inc. 2025 . The average Capricor Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Capricor Therapeutics, Inc. EBITDA forecast 2025. The average Capricor Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
12 Capricor Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Capricor Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.15 | -2.20 |
| 38.55% | 91.30% | |
| P/E | negative | |
| EV/Sales | 2,482.73 |
12 Analysts have issued a Capricor Therapeutics, Inc. forecast for earnings per share. The average Capricor Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Capricor Therapeutics, Inc....
Current Capricor Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| B. Riley Securities |
Locked
➜
Locked
|
Locked | Dec 15 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Dec 10 2025 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | Dec 08 2025 |
| Maxim Group |
Locked
➜
Locked
|
Locked | Dec 04 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Dec 03 2025 |
| Roth Capital |
Locked
➜
Locked
|
Locked | Nov 12 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 25 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
B. Riley Securities:
Locked
➜
Locked
|
Dec 15 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Dec 10 2025 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Dec 08 2025 |
|
Locked
Maxim Group:
Locked
➜
Locked
|
Dec 04 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Dec 03 2025 |
|
Locked
Roth Capital:
Locked
➜
Locked
|
Nov 12 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 25 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
